Shots:

• The EMA’s CHMP has adopted a positive opinion recommending the MAA of Centus’ Equidacent (bevacizumab)- a biosimilar to Roche's Avastin to treat carcinoma of the colon or rectum- breast cancer- NSCLC- RCC- epithelial ovarian- fallopian tube or primary peritoneal cancer- and carcinoma of the cervix
• Equidacent will be available as 25 mg/ml as the solution for infusion targeting VEGF and act by inhibiting the binding of VEGF to its receptors on endothelial cell
• The company anticipates EC’s decision in ~60days. The clinical data demonstrated that Equidacent has comparable quality- safety- and efficacy to Avastin

  Ref: PRNewswire | Image: PharmaShots